The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders. Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important ...
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers. Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers ...
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours.
1.3 Drug-resistant TB Trends at regional level vary (Fig. 1.3.3). Between 2020 and 2024, there were estimated increases in the number of people who developed MDR/RR-TB in the WHO Region of the Americas and the WHO South-East Asia Region. In contrast, the estimated number of people developing MDR/RR-TB each year has been declining since 2015 in both the African and Eastern Mediterranean regions ...
World malaria report 2025 Antimalarial drug resistance challenging progress Each year, WHO’s World malaria report provides a comprehensive and up-to-date assessment of trends in malaria control and elimination across the globe.
The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB).
XDR-TB, an abbreviation for extensively drug-resistant tuberculosis (TB), is a form of TB that is caused by a strain of M. tuberculosis complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other Group A drug (bedaquiline or linezolid). While there are some ...
WHO has released the Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030, a landmark roadmap to address the growing threat of drug resistance and safeguard progress toward ending AIDS and the epidemics of hepatitis B, hepatitis C and sexually transmitted infections (STIs) as public health concerns.